Agendia data reveals impact of MammaPrint on adjuvant treatment decisions in breast c

[News]

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, has presented new prospective data demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence assay, MammaPrint, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint, in clinical decision-making for patients with early-stage breast cancer in Germany.

More... (http://www.news-medical.net/news/20161222/Agendia-data-reveals-impact-of-MammaPrint-on-adjuvant-treatment-decisions-in-breast-cancer-patients.aspx)